VanEck Pharmaceutical ETF PPH Strategy
Strategy
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
|
Ticker
|
Name
|
Share Class Type
|
Investment Status
|
Morningstar Rating for Funds
Overall
|
Medalist Rating
Overall
|
Inception Date
|
Total Net Assets for Share Class
|
Adjusted Expense Ratio
|
Fee Level
Distribution
|
Minimum Initial Investment
|
1-Year Net Flow
|
|---|---|---|---|---|---|---|---|---|---|---|---|
PPH
| VanEck Pharmaceutical ETF | ETF | Open | — | — | 0.360% | — | — | — | ||
| — | VanEck Pharmaceutical ETF | ETF | Open | — | — | 0.360% | — | — | — | ||
PPH
| VanEck Pharmaceutical ETF | ETF | Open | $1.03B | 0.360% | — | — | $260.65M |